Hansa Biopharma AB (publ)

Stockholm Stock Exchange:HNSA.ST

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

Sweden

Market Cap

USD 163.86 M

Share Price

USD 2.50

Avg Daily Volume

163,653

Change (1 day)

1.27%

Change (1 year)

-45.96%

Change (YTD)

-29.44%

Hansa Biopharma AB (publ) Total Assets for the year ending December 31, 2024: USD 72.06 M

Hansa Biopharma AB (publ) Total Assets is USD 72.06 M for the year ending December 31, 2024, a -28.29% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Hansa Biopharma AB (publ) Total Assets for the year ending December 31, 2023 was USD 100.48 M, a -37.65% change year over year.
Hansa Biopharma AB (publ) Total Assets for the year ending December 31, 2022 was USD 161.15 M, a 44.51% change year over year.
Hansa Biopharma AB (publ) Total Assets for the year ending December 31, 2021 was USD 111.51 M, a -35.86% change year over year.
Hansa Biopharma AB (publ) Total Assets for the year ending December 31, 2020 was USD 173.86 M, a 146.00% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

Stockholm Stock Exchange: HNSA.ST

Hansa Biopharma AB (publ)

CEO	Ms. Renee Aguiar-Lucander
IPO Date	Oct. 17, 2007
Location	Sweden
Headquarters	PO Box 785
Employees	138
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.